ZA98214B - Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. - Google Patents
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.Info
- Publication number
- ZA98214B ZA98214B ZA9800214A ZA98214A ZA98214B ZA 98214 B ZA98214 B ZA 98214B ZA 9800214 A ZA9800214 A ZA 9800214A ZA 98214 A ZA98214 A ZA 98214A ZA 98214 B ZA98214 B ZA 98214B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- ingestion
- inhalation
- copolymer
- multiple sclerosis
- Prior art date
Links
- 230000037406 food intake Effects 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- General Preparation And Processing Of Foods (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA98214B true ZA98214B (en) | 1999-08-11 |
Family
ID=11069682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9800214A ZA98214B (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0975351B1 (https=) |
| JP (1) | JP4216342B2 (https=) |
| KR (1) | KR20000070058A (https=) |
| CN (1) | CN100528222C (https=) |
| AT (1) | ATE356608T1 (https=) |
| AU (1) | AU737287B2 (https=) |
| BR (1) | BRPI9807076B8 (https=) |
| CA (1) | CA2277365C (https=) |
| CZ (1) | CZ297983B6 (https=) |
| DE (1) | DE69837324T2 (https=) |
| EA (1) | EA003128B1 (https=) |
| HU (1) | HU226612B1 (https=) |
| IL (2) | IL119989A0 (https=) |
| NZ (1) | NZ336690A (https=) |
| PL (1) | PL193300B1 (https=) |
| SK (1) | SK284029B6 (https=) |
| WO (1) | WO1998030227A1 (https=) |
| ZA (1) | ZA98214B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279172B2 (en) | 1998-07-23 | 2007-10-09 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| JP2003521448A (ja) * | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6872739B1 (en) * | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| EP1187612B1 (en) * | 1999-06-04 | 2005-01-26 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| WO2001060392A1 (en) * | 2000-02-18 | 2001-08-23 | Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| CA2411536A1 (en) * | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| SI1459065T1 (sl) | 2001-12-04 | 2010-11-30 | Teva Pharma | Postopki za merjenje potentnosti glatiramer acetata |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| CA2514125A1 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN105884866B (zh) * | 2015-01-26 | 2021-04-20 | 漳州未名博欣生物医药有限公司 | 格拉替雷的化学合成方法 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN112649537B (zh) * | 2015-04-28 | 2024-03-29 | 深圳翰宇药业股份有限公司 | 多肽混合物高效液相色谱分析方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HUE071047T2 (hu) | 2016-08-31 | 2025-07-28 | Mapi Pharma Ltd | Glatiramer-acetátot tartalmazó depórendszerek |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| JP2020525459A (ja) | 2017-06-26 | 2020-08-27 | アンスティテュ・パストゥール | Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
-
1997
- 1997-01-10 IL IL11998997A patent/IL119989A0/xx unknown
-
1998
- 1998-01-12 SK SK931-99A patent/SK284029B6/sk not_active IP Right Cessation
- 1998-01-12 HU HU0001917A patent/HU226612B1/hu unknown
- 1998-01-12 CA CA2277365A patent/CA2277365C/en not_active Expired - Lifetime
- 1998-01-12 DE DE69837324T patent/DE69837324T2/de not_active Expired - Lifetime
- 1998-01-12 AT AT98901745T patent/ATE356608T1/de not_active IP Right Cessation
- 1998-01-12 EP EP98901745A patent/EP0975351B1/en not_active Expired - Lifetime
- 1998-01-12 ZA ZA9800214A patent/ZA98214B/xx unknown
- 1998-01-12 WO PCT/US1998/000375 patent/WO1998030227A1/en not_active Ceased
- 1998-01-12 PL PL334566A patent/PL193300B1/pl unknown
- 1998-01-12 NZ NZ336690A patent/NZ336690A/en not_active IP Right Cessation
- 1998-01-12 BR BRPI9807076A patent/BRPI9807076B8/pt not_active IP Right Cessation
- 1998-01-12 AU AU58195/98A patent/AU737287B2/en not_active Expired
- 1998-01-12 CN CNB988031221A patent/CN100528222C/zh not_active Expired - Lifetime
- 1998-01-12 EA EA199900621A patent/EA003128B1/ru not_active IP Right Cessation
- 1998-01-12 JP JP53110898A patent/JP4216342B2/ja not_active Expired - Lifetime
- 1998-01-12 KR KR1019997006278A patent/KR20000070058A/ko not_active Ceased
- 1998-01-12 CZ CZ0243799A patent/CZ297983B6/cs not_active IP Right Cessation
-
1999
- 1999-07-06 IL IL130820A patent/IL130820A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279172B2 (en) | 1998-07-23 | 2007-10-09 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ297983B6 (cs) | 2007-05-16 |
| DE69837324T2 (de) | 2007-11-29 |
| DE69837324D1 (de) | 2007-04-26 |
| CZ243799A3 (cs) | 2000-06-14 |
| AU737287B2 (en) | 2001-08-16 |
| PL193300B1 (pl) | 2007-01-31 |
| BR9807076B1 (pt) | 2013-10-29 |
| ATE356608T1 (de) | 2007-04-15 |
| SK284029B6 (sk) | 2004-08-03 |
| WO1998030227A1 (en) | 1998-07-16 |
| PL334566A1 (en) | 2000-03-13 |
| BRPI9807076B8 (pt) | 2021-05-25 |
| HUP0001917A3 (en) | 2001-12-28 |
| CN1249690A (zh) | 2000-04-05 |
| CA2277365A1 (en) | 1998-07-16 |
| NZ336690A (en) | 2001-05-25 |
| EA199900621A1 (ru) | 2000-02-28 |
| EP0975351A4 (en) | 2002-05-15 |
| HU226612B1 (en) | 2009-04-28 |
| EP0975351A1 (en) | 2000-02-02 |
| EA003128B1 (ru) | 2003-02-27 |
| JP2001511121A (ja) | 2001-08-07 |
| CN100528222C (zh) | 2009-08-19 |
| EP0975351B1 (en) | 2007-03-14 |
| KR20000070058A (ko) | 2000-11-25 |
| BR9807076A (pt) | 2000-05-02 |
| IL119989A0 (en) | 1997-04-15 |
| IL130820A (en) | 2007-03-08 |
| HK1025737A1 (en) | 2000-11-24 |
| HUP0001917A2 (hu) | 2000-10-28 |
| SK93199A3 (en) | 2000-11-07 |
| JP4216342B2 (ja) | 2009-01-28 |
| AU5819598A (en) | 1998-08-03 |
| CA2277365C (en) | 2011-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA98214B (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. | |
| IL113812A (en) | Copolymer-1 pharmaceutical compositions containing it and its use | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| BG103793A (en) | COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| ZA943744B (en) | Therapeutic substituted guanidines | |
| NZ503308A (en) | Alpha-ketoamide multicatalytic protease inhibitors | |
| IL141157A0 (en) | Salt form of pantoprazole and pharmaceutical compositions containing the same | |
| AP2000001947A0 (en) | Novel crystalline forms of an antiviral benzidazole compound. | |
| YU79202A (sh) | Peptid koji modulira trombopoetinski receptor | |
| MXPA94009086A (es) | Guanidinas sustituidas terapeuticas. | |
| AU4011300A (en) | Compositions and methods for the treatment of immune related diseases | |
| AU9731198A (en) | Histogranin peptide and their analgesic use | |
| BG103632A (en) | Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment | |
| WO1996021468A3 (en) | Chemically modified interferon | |
| AU6849198A (en) | Neurotrypsin | |
| IL111805A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of aphthae | |
| IL111804A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of constipation | |
| EP0714404A4 (en) | ANTI-FLAMMABLE PEPTIDES | |
| GB9015774D0 (en) | Novel treatment | |
| GR1002385B (el) | Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν. | |
| DE69929802D1 (en) | Lta4 hydrolase-hemmer | |
| MY118194A (en) | Pharmaceutical compositions for use in inhibiting bone resorption |